Diastolic heart failure in the elderly and the potential role of aldosterone antagonists

Drugs and Aging

Volumn 23, Issue 4, 2006, Pages 299-308

  Kumar, Ashwani ^a   Meyerrose, Gary ^a   Sood, Vineeta ^a   Roongsritong, Chanwit ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALTIZIDE; CANRENONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; SPIRONOLACTONE;

CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ECHOCARDIOGRAPHY; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION TIME; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTOLIC HYPERTENSION;

AGED; AGING; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CLINICAL TRIALS; DIASTOLE; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 33744821628     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623040-00003     Document Type: Review

References (57)

1. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951-7
2. Kannel WB. Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J 1987; 8 Suppl. F: 23-6
3. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-e82
4. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004; 55: 373-94
5. Redfield MM, Jacobsen SJ, Burnett Jr JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202
6. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387-93
7. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-9
8. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-74
9. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients ≥65 years of age. Am J Cardiol 2001; 87: 413-9
10. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2001; 37: 1042-8
11. Vasan R, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948-55
12. O'Conner CM, Gattis WA, Shaw L, et al. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 2000; 86: 863-7
13. Judge KW, Pawitan Y, Caldwell J, et al. Congestive heart failure symptoms in patients with preserved left ventricular systolic function: analysis of the CASS registry. J Am Coll Cardiol 1991; 18: 377-82
14. Aurigemma GP, Williams HG. Diastolic heart failure. N Engl J Med 2004; 351: 1097-105
15. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001; 104: 779-82
16. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998; 19: 990-1003
17. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000; 101: 2118-21
18. Bryg RJ, Williams GA, Labovitz AJ. Effect of aging on left ventricular diastolic filling in normal subjects. Am J Cardiol 1987; 59: 971-4
19. Rakowski H, Appleton C, Chan KL, et al. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 1996; 9: 736-60
20. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32: 865-75
21. Yamaguchi H, Yoshida J, Yamamoto K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 55-60
22. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction, comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601
23. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic and diastolic dysfunction. Am J Med 2001; 111: 274-9
24. Roongsritong C, Qaddour A, Cox SL, et al. Brain natriuretic peptide and diastolic dysfunction in the elderly: influence of gender. Congest Heart Fail 2005; 11: 65-7
25. Kitzman DW. Diastolic function in the elderly, genesis and diagnostic and therapeutic implications. Cardiol Clin 2000; 18: 597-617
26. Gaasch WH, Izzi G. Clinical diagnosis and management of left ventricular diastolic dysfunction. In: Hori M, Suga H, Baan J, et al., editors. Cardiac mechanics and function in the normal and diseased heart. New York: Springer-Verlag, 1989: 296
27. Gaasch WH, Blaustein AS, LeWinter MM. Heart failure and clinical disorders of left ventricular diastolic dysfunction. In: Gaasch WH, LeWinter MM, editors. Left ventricular diastolic dysfunction and heart failure. Philadelphia (PA): Lea and Febiger, 1994: 245-58
28. Abd-Allah NM, Hassan FH, Esmat AY, et al. Age dependence of the levels of plasma norepinephrine, aldosterone, renin activity and urinary vanillylmandelic acid in normal and essential hypertensives. Biol Res 2004; 37: 95-106
29. Daniel KR, Brosnihan B, Fray B, et al. Renin-angiotensin-aldosterone system activation in diastolic heart failure: comparison with systolic heart failure and age-matched normal subjects [abstract]. J Am Coll Cardiol 2005; 45: 130A
30. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001; 38: 1227-32
31. Brilla C, Weber K. Reactive and reparative myocardial fibrosis in arterial hypertension in rats. Cardiovasc Res 1992; 26: 671-7
32. Young M, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269: E657-62
33. Delcayre C, Silvestre JS. Aldosterone and the heart: towards a physiological function? Cardiovasc Res 1999; 43: 7-12
34. Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 2000; 47: 1-3
35. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: 802-10
36. Connell MC, Davies E. The new biology of aldosterone. J Endocrinol 2005; 186: 1-20
37. Soylu A, Temizhan A, Duzenli MA, et al. The influence of aldosterone on development of left ventricular geometry and hypertrophy in patients with essential hypertension. Jpn Heart J 2004; 45: 807-21
38. Bravo EL. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. Curr Hypertens Rep 2003; 5: 122-5
39. Stier Jr CT, Koenig S, Lee DY, et al. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). Heart Dis 2003; 5: 102-18
40. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96: 610-1
41. Gaasch WH, Schick EC, Zile MR. Management of left ventricular diastolic dysfunction. In: Smith TW, editor. Cardiovascular therapeutics: a companion to Braunwald's Heart Disease. Philadelphia (PA): WB Saunders, 1996: 237-42
42. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95: 2007-14
43. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104: 1615-21
44. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17
45. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81
46. Brilla C, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A
47. Lijnen P, Petrov V. Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Method Find Exp Clin Pharmacol 1999; 21: 215-27
48. Silvestre J, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-701
49. Lacolley P, Safer ME, Lucet B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001; 37: 662-7
50. Degre S, Detry JM, Unger P, et al. Effects of spironolactone-altizide on left ventricular hypertrophy. Acta Cardiol 1998; 53: 261-7
51. Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40: 647-52
52. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25: 837-42
53. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril and eplerenone/enalapril combination in patients with essential hypertension and left ventricular hypertrophy: 4E Left Ventricular Hypertrophy Study. Circulation 2003; 108: 1831-8
54. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110: 558-65
55. Roongsritong C, Sutthiwan P, Bradley J, et al. Spironolactone improves diastolic function in the elderly. Clin Cardiol 2005; 28: 484-7
56. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000; 102: 2700-6
57. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin- aldosterone system. J Renin Angiotensin Aldosterone Syst 2004; 5: 102-8